Lederer & Associates Investment Counsel CA Has $2.32 Million Holdings in Stryker Co. (NYSE:SYK)

Lederer & Associates Investment Counsel CA cut its holdings in shares of Stryker Co. (NYSE:SYK) by 3.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,433 shares of the medical technology company’s stock after selling 249 shares during the quarter. Stryker comprises 1.6% of Lederer & Associates Investment Counsel CA’s investment portfolio, making the stock its 12th largest holding. Lederer & Associates Investment Counsel CA’s holdings in Stryker were worth $2,316,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of SYK. Centaurus Financial Inc. lifted its holdings in shares of Stryker by 11.3% during the second quarter. Centaurus Financial Inc. now owns 1,047 shares of the medical technology company’s stock worth $356,000 after buying an additional 106 shares during the last quarter. Czech National Bank raised its stake in shares of Stryker by 8.1% in the third quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock valued at $25,231,000 after purchasing an additional 5,235 shares in the last quarter. HBW Advisory Services LLC acquired a new position in shares of Stryker in the third quarter valued at $42,000. GAMMA Investing LLC raised its stake in shares of Stryker by 38.7% in the third quarter. GAMMA Investing LLC now owns 2,901 shares of the medical technology company’s stock valued at $1,048,000 after purchasing an additional 810 shares in the last quarter. Finally, Diversified Trust Co raised its stake in shares of Stryker by 5.8% in the third quarter. Diversified Trust Co now owns 14,581 shares of the medical technology company’s stock valued at $5,268,000 after purchasing an additional 800 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 0.1 %

NYSE:SYK opened at $390.90 on Monday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The business’s 50-day moving average price is $376.68 and its two-hundred day moving average price is $363.02. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $149.02 billion, a price-to-earnings ratio of 50.37, a PEG ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 EPS. On average, equities analysts expect that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were issued a dividend of $0.84 per share. The ex-dividend date of this dividend was Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Canaccord Genuity Group upped their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. BTIG Research upped their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Royal Bank of Canada upped their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $420.00 price target (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $419.37.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.